About RealSeq Biosciences

Our Story

RealSeq Biosciences was born out of the recognition that the vast amounts of dynamic biological information in RNA was being overlooked because RNA fragments are too difficult to detect and analyze.

Determined to realize the potential of this next-generation analyte, our founders Sergio Barberan-Soler, Ph.D, Anne Scholz, MBA., and Sergei Kazakov, Ph.D. began developing the RiboMarker® RNA fragmentomics platform to unlock RNA analysis for all.

Founded in 2019 and built on NIH Phase I and II grants, we are determined to bring the advancements in diagnostics that RNA fragmentomics can provide to the world. After reaching the finals of the 2022 BioTools Innovator competition, we completed seed fundraising to continue our mission of realizing RNA fragmentomics.

Our Vision

Realizing RNA fragmentomics to advance diagnostics and improve health.

Our Mission

To better lives by enabling next-generation diagnostics through the development of RNA fragmentomics to discover new biomarkers and realize deeper transcriptome insights.

Meet Our Team

  • Sergio Barberan-Soler, Ph.D.

    Co-founder and CEO

    Linkedin

  • Anne Scholz, MBA.

    Co-founder and COO

    Linkedin

  • Sergei Kazakov, Ph.D.

    Co-founder and CSO

    Linkedin

Our Board & Advisors

  • Robert Feldman

    Board Member

  • John Grant

    Board Member

  • Mikael Kubista, Scientific Advisor

    Mikael Kubista

    Scientific Advisor

  • Brian Johnston

    Co-Founder and Board Member

Interested in Joining?